Atlas Trials

A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.

Clinical trial NCT02094053 · COMPLETED

Trial details

NCT number
NCT02094053
Sponsor
Eisai Co., Ltd.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Down Syndrome
Start date
2013-09-12
Primary completion
2016-09-16
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.